Amendments to the Claims:

Please cancel claims 19 and 26 and add new claims 43-54. Please amend claims 1-18, 20-21, 23-25, and 42 as follows.

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently amended) A compound of Formula (I):



(I)

or pharmaceutically acceptable salt thereof, wherein:

R^1 is H or C_1-C_8 alkyl;

R^2 is C_1-C_8 alkyl;

R^3 is H, arylalkyl-O-, arylalkyl-N(R^5)-, aryl-N(R^5)-, or heteroaryl; or

R^3 is [[H,]]aryl~~, arylalkyl-O-, arylalkyl-N(R^5)-, aryl-N(R^5)-, or heteroaryl, wherein said aryl~~ which is optionally substituted with up to two substituents selected from C_{1-8} alkyl, halogen, perhaloalkyl, and alkoxy;

R^4 is H, arylalkyl-O-, alkoxy, or aryloxy; and

R^5 is H, C_1-C_8 alkyl, aryl, ~~C_{1-8} alkenyl~~ C_{2-8} alkenyl, heteroaryl, arylalkyl, heteroarylalkyl, perhaloalkyl, or allyl;

with the provisos:

a) at least one of R^3 and R^4 is other than H;

b) when R^3 is arylalkyl-N(R^5)- or aryl-N(R^5)- and R^4 is H, then R^1 is H;

c) when R^1 is H, R^2 is CH_3 and R^3 is 2-chlorophenyl, then R^4 is other than H; and

d) when R^1 is H, R^2 is CH_3 and R^3 is 2-thienyl, then R^4 is other than methoxy.

2. (Currently amended) The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein:

R^1 is H or C_1-C_8 alkyl;

R^2 is C_1-C_8 alkyl;

R^3 is H, aryl, arylalkyl-O-, arylalkyl-N(R^5)-, or aryl-N(R^5)- wherein said aryl is optionally substituted with up to two substituents selected from C_{1-8} alkyl, halogen, perhaloalkyl, and alkoxy;

R^4 is H or aryloxy; and

R^5 is H, C_1-C_8 alkyl, aryl, ~~C_{1-8} alkenyl~~ C_{2-8} alkenyl, heteroaryl, arylalkyl, heteroarylalkyl, perhaloalkyl, or allyl.

3. (Currently amended) A compound of claim 1, or pharmaceutically acceptable salt thereof, having Formula (**Ia**):



(Ia)

or pharmaceutically acceptable salt form thereof.

4. (Currently amended) A compound of claim 1, or pharmaceutically acceptable salt thereof, having Formula (**Ib**):



(Ib)

or pharmaceutically acceptable salt form thereof.

5. (Currently amended) The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein:

R^1 is H or C_1-C_8 alkyl;

R^2 is C_1-C_8 alkyl;

R^3 is arylalkyl-O-, arylalkyl-N(R^5)-, or aryl-N(R^5)-;

R^4 is H; and

R^5 is H, C_1-C_8 alkyl, aryl, ~~C_{1-8} alkenyl~~ C_{2-8} alkenyl, heteroaryl, arylalkyl, heteroarylalkyl, perhaloalkyl, or allyl.

6. (Currently amended) The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein:

R^1 is H or C_1-C_8 alkyl;

R^2 is C_1-C_8 alkyl;

R^3 is arylalkyl-O-, arylalkyl-N(R^5)-, or aryl-N(R^5)-;

R^4 is H; and

R^5 is H, C_1-C_8 alkyl, or aryl.

7. (Currently amended) The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein:

R^1 is H or C_1-C_8 alkyl;

R^2 is C_1-C_8 alkyl;

R^3 is arylalkyl-O-; and

R^4 is H.

8. (Currently amended) The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein:

R^1 is H or C_1-C_8 alkyl;

R^2 is C_1-C_8 alkyl;

R^3 is H; and

R^4 is arylalkyl-O-.

9. (Currently amended) The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein:

R^1 is H;

R^2 is C_1-C_4 alkyl;

R^3 is arylalkyl-O-; and

R^4 is H.

10. (Currently amended) The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein:

R^1 is H;

R^2 is C_1-C_8 alkyl;

R^3 is arylalkyl-N(R^5)-;

R^4 is H; and

R^5 is H, C_1-C_8 alkyl, or aryl.

11. (Currently amended) The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein:

R^1 is H;

R^2 is methyl;

R^3 is phenyl, phenylalkyl-O-, phenylalkyl-N(R^5)-, or phenyl-N(R^5)-;

R^4 is H; and

R^5 is H.

12. (Currently amended) The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein:

R^1 is H;

R^2 is methyl;

R^3 is H; and

R^4 is phenylalkyl-O-.

13. (Currently amended) The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein:

R^1 is H;

R^2 is methyl;

R^3 is phenyl optionally substituted with up to two halogens, or R^3 is pyridinyl; and

R^4 is H or alkoxy.

14. (Currently amended) The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein:

R^1 is H;

R^2 is methyl;

R^3 is phenyl optionally substituted with up to two fluoro; and

R^4 is H or methoxy.

15. (Currently amended) The compound of claim 1, or pharmaceutically acceptable salt thereof, wherein:

R^1 is H;

R^2 is methyl;

R^3 is pyridinyl; and

R^4 is H.

16. (Currently amended) A compound of ~~any one of claims 1 to 4~~ claim 1, selected from:

a) 7-benzyloxy-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

b) 1-methyl-7-(1-phenyl-ethoxy)-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

c) 1-methyl-7-phenethyloxy-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

d) 1-methyl-7-(3-phenyl-propoxy)-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

e) benzyl-(5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-amine;

f) (5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-(1'-phenyl-ethyl)-amine;

g) benzyl-methyl-(5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-amine;

h) (5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-phenethyl-amine;

i) (5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-(3-phenyl-propyl)-amine;

j) (5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-phenyl-amine; and

k) 1-methyl-8-phenyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

or pharmaceutically acceptable salt thereof.

17. (Currently amended) A compound of ~~any one of claims 1 to 4~~ claim 1, selected from:

a) 8-Benzyloxy-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

b) 7-Benzyloxy-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

c) 1-Methyl-8-phenyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

d) 7-Methoxy-1-methyl-8-phenyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

e) 8-(2-Fluoro-phenyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

f) 8-(3-Fluoro-phenyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

g) 8-(4-Fluoro-phenyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

h) 8-(2,6-Difluoro-phenyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

i) 8-(2,3-Difluoro-phenyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

j) 8-(2,5-Difluoro-phenyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

k) 1-Methyl-8-pyridin-3-yl-2,3,4,5-tetrahydro-1H-benzo[d]azepine; and

l) 1-Methyl-8-pyridin-2-yl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

or pharmaceutically acceptable salt thereof.

18. (Currently amended) A composition comprising a compound of claim 1, or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

19. (Canceled)

20. (Currently amended) A method of treating a disorder ~~The method of claim 19 wherein the disorders of the central nervous system are~~ selected from depression, atypical depression, ~~bipolar disorders~~, anxiety ~~disorders~~, obsessive-compulsive disorder[[s]], social phobia[[s or]], panic states, ~~sleep disorders,~~ sexual dysfunction, psychoses, schizophrenia, ~~migraine and other conditions associated with cephalic pain or other pain, raised intracranial pressure,~~ epilepsy, ~~personality disorders, age related behavioral disorders, behavioral disorders associated with~~

~~dementia, organic mental disorders, mental disorders in childhood, aggressivity, age related memory disorders, chronic fatigue syndrome~~, drug and alcohol addiction, and obesity, ~~bulimia, anorexia nervosa and premenstrual tension~~ comprising administering to a patient in need of said treating a therapeutically effective amount of a compound of claim 1, or pharmaceutically acceptable salt thereof.

21. (Currently amended) The method according to claim 19 wherein the disorder ~~of the central nervous system~~ is obesity.

22. (Original) The method according to claim 19 wherein the sexual dysfunction is male erectile dysfunction.

23. (Currently amended) A method of decreasing food intake of a mammal comprising administering to said mammal a therapeutically effective amount of a compound of claim 1, or pharmaceutically acceptable salt thereof.

24. (Currently amended) A method of inducing satiety in a mammal comprising administering to said mammal a therapeutically effective amount of a compound of claim 1, or pharmaceutically acceptable salt thereof.

25. (Currently amended) A method of controlling weight gain of a mammal comprising administering to said mammal a therapeutically effective amount of a compound of claim 1, or pharmaceutically acceptable salt thereof.

26-41. (Canceled)

42. (Currently amended) A method for preparing a pharmaceutical composition comprising the step of mixing a compounds of claim 1, or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

43. (New) The method according to claim 19 wherein the disorder is depression.

44. (New) The method according to claim 19 wherein the disorder is anxiety.

45. (New) The method according to claim 19 wherein the disorder is obsessive-compulsive disorder.

46. (New) The method according to claim 19 wherein the disorder is social phobia.

47. (New) The method according to claim 19 wherein the disorder is panic states.

48. (New) The method according to claim 19 wherein the disorder is psychoses.

49. (New) The method according to claim 19 wherein the disorder is schizophrenia.

50. (New) The method according to claim 19 wherein the disorder is selected from drug and alcohol addiction.

51. (New) A compound of claim 1 selected from:

a) (R)-7-benzyloxy-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

b) (R)-1-methyl-7-(1-phenyl-ethoxy)-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

c) (R)-1-methyl-7-phenethyloxy-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

d) (R)-1-methyl-7-(3-phenyl-propoxy)-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

e) (R)-benzyl-(5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-amine;

f) (R)- (5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-(1'-phenyl-ethyl)-amine;

g) (R)-benzyl-methyl-(5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-amine;

h) (R)-(5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-phenethyl-amine;

i) (R)-(5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-(3-phenyl-propyl)-amine;

j) (R)-(5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-phenyl-amine; and

k) (R)-1-methyl-8-phenyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

or pharmaceutically acceptable salt thereof.

52. (New) A compound of claim 1 selected from:

a) (S)-7-benzyloxy-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

b) (S)-1-methyl-7-(1-phenyl-ethoxy)-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

c) (S)-1-methyl-7-phenethyloxy-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

d) (S)-1-methyl-7-(3-phenyl-propoxy)-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

e) (S)-benzyl-(5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-amine;

f) (S)- (5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-(1'-phenyl-ethyl)-amine;

g) (S)-benzyl-methyl-(5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-amine;

h) (S)-(5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-phenethyl-amine;

i) (S)-(5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-(3-phenyl-propyl)-amine;

j) (S)-(5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-phenyl-amine; and

k) (S)-1-methyl-8-phenyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

or pharmaceutically acceptable salt thereof.

53. (New) A compound of claim 1 selected from:

a) (R)-8-Benzyloxy-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

b) (R)-7-Benzyloxy-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

c) (R)-1-Methyl-8-phenyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

d) (R)-7-Methoxy-1-methyl-8-phenyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

e) (R)-8-(2-Fluoro-phenyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

f) (R)-8-(3-Fluoro-phenyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

g) (R)-8-(4-Fluoro-phenyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

h) (R)-8-(2,6-Difluoro-phenyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

i) (R)-8-(2,3-Difluoro-phenyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

j) (R)-8-(2,5-Difluoro-phenyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

k) (R)-1-Methyl-8-pyridin-3-yl-2,3,4,5-tetrahydro-1H-benzo[d]azepine; and

l) (R)-1-Methyl-8-pyridin-2-yl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

or pharmaceutically acceptable salt thereof.

54. (New) A compound of claim 1 selected from:

a) (S)-8-Benzyloxy-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

b) (S)-7-Benzyloxy-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

c) (S)-1-Methyl-8-phenyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

d) (S)-7-Methoxy-1-methyl-8-phenyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

e) (S)-8-(2-Fluoro-phenyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

f) (S)-8-(3-Fluoro-phenyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

g) (S)-8-(4-Fluoro-phenyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

h) (S)-8-(2,6-Difluoro-phenyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

i) (S)-8-(2,3-Difluoro-phenyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

j) (S)-8-(2,5-Difluoro-phenyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

k) (S)-1-Methyl-8-pyridin-3-yl-2,3,4,5-tetrahydro-1H-benzo[d]azepine; and

l) (S)-1-Methyl-8-pyridin-2-yl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

or pharmaceutically acceptable salt thereof.